

FIG. 2C – Anti-CLL-1 Binding Molecules

	FR1	CDR1	FR2	CDR2	FR3
24C1_VL	DIQLTQSPSSLSASVGDRVSFTQ	QASQDINNFLN	WYQQKPGKAPKLLIY	DASNLET	GVPS
24C8_VL	DIQLTQSPSSLSASVGDRVSFTQ	QASQDINNFLN	WYQQKPGKAPKLLIY	DASNLET	GVPS
20C5.1_VL	DIQMTQSPSSLSASVGDRVTITC	RASQSISSYLN	WYQQKPGKAPKLLIS	GASSLKS	GVPS
20C5.2_VL	EIVMTQSPATLSVSPGERATLSC	RASQSVSSLLT	WYQQKPGQAPRLLI	FGASTRAT	GIPA
	:*	:*****:***.*	*:*.:::*	:****.:. .*.*****:***:***	.**.*:***:

	FR3	CDR3	FR4
24C1_VL	RFSGSGSGTDFTFTISSLQPED	IATYYCQQYGNLPFT	FGGGTKVEIKR
24C8_VL	RFSGSGSGTDFTFTISSLQPED	IATYYCQQYGNLPFT	FGGGTKVEIKR
20C5.1_VL	RFSGSGSGTDFTLTISLPPED	FATYYCQQSYSTPIT	FGQGTRLEIKR
20C5.2_VL	RFSGSGSGTGFTLTISLQSE	DFAVYYCQQYDTWPF	TGPGTKVDFKR
	*****.**:*****	.**:*.******	.*:*** **::::**

<u>FIG. 2D</u>	SEQ ID NO:			
	VL	CDR1	CDR2	CDR3
24C1 VL	129	105	109	113
24C8 VL	130	106	110	114
20C5.1 VL	131	107	111	115
20C5.2 VL	132	108	112	116